Therapeutic Advances in Urology

SJR Rank #4,110H-index: 48SJR: 1.111Best quartile: Q1Open AccessAPC: US$2,650Listed in DOAJ
Journal website: aims, scope and author guidelines
Publisher

SAGE Publications Inc.

Country

United States

Type

journal

SJR by Edition

2022202500.30.60.91.2

Subject Categories

  • UrologyQ1

Areas: Medicine

Most published research topics

Urinary Bladder and Prostate ResearchProstate Cancer Diagnosis and TreatmentBladder and Urothelial Cancer TreatmentsPelvic floor disorders treatmentsProstate Cancer Treatment and ResearchUrinary Tract Infections ManagementKidney Stones and Urolithiasis TreatmentsSexual function and dysfunction studiesRenal cell carcinoma treatmentUrological Disorders and Treatments

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs03570105140

Documents per Year

20222025015304560

Detailed Information

ISSN

1756-2872, 1756-2880

SJR Best Quartile

Q1

Region

Northern America

Citations per Document (2 years)

3.41

References per Document

34.94

Coverage

2009-2026

Scope

Therapeutic Advances in Urology is an open access journal which delivers the highest-quality peer-reviewed open access original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of urological conditions. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in urology and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area. The editors welcome original research articles across all areas of urology. The journal publishes original research articles and review articles primarily. Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). The journal endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of the first patient enrolment.

Metrics from SCImago Journal Rank 2025. View on SCImago